Stock analysts at StockNews.com assumed coverage on shares of Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) in a research report issued to clients and investors on Tuesday. The brokerage set a “hold” rating on the stock.
Diffusion Pharmaceuticals Stock Down 2.5 %
Shares of DFFN opened at $3.68 on Tuesday. Diffusion Pharmaceuticals has a 12-month low of $3.55 and a 12-month high of $8.74. The business has a 50-day simple moving average of $4.03 and a two-hundred day simple moving average of $5.28. The stock has a market cap of $7.51 million, a PE ratio of -0.48 and a beta of 1.82.
Hedge Funds Weigh In On Diffusion Pharmaceuticals
A hedge fund recently raised its stake in Diffusion Pharmaceuticals stock. Renaissance Technologies LLC boosted its position in Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN – Get Rating) by 8.3% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,324,202 shares of the company’s stock after purchasing an additional 101,100 shares during the period. Renaissance Technologies LLC owned 64.94% of Diffusion Pharmaceuticals worth $331,000 at the end of the most recent quarter. 9.24% of the stock is owned by institutional investors and hedge funds.
About Diffusion Pharmaceuticals
Diffusion Pharmaceuticals, Inc is a biopharmaceutical company, which engages in developing novel therapies that enhance the body’s ability to deliver oxygen. The firm’s product candidate, Trans Sodium Crocetinate, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia.
Read More
- Get a free copy of the StockNews.com research report on Diffusion Pharmaceuticals (DFFN)
- Surging Over 100%: Small Cap Electric Boat Maker Makes Waves
- Sleeper AI-Play MongoDB Could Triple In Size
- SunCar Technology Stock Overheats…Will it Rise Again?
- OPEC Meeting: Is Saudi Arabia Trying to Squeeze the Oil Market?
- Buffett-Backed BYD Caught In The Chinese Government’s Stimulus
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
